Introduction
One of the common features of solid human tumors is presence of abnormal number of chromosomes, a state often referred as "aneuploidy" [1] . Previous studies indicate that a mechanism that sustains aneuploidy in tumour cells is the over-expression of high levels of monopolar spindle 1 (Mps1) kinase [2] . Mps1, also known as threonine and tyrosine kinase (TTK), is a dual specificity protein kinase, essential for safeguarding proper chromosome alignment and segregation during mitosis [2] . Due to its importance for the viability of tumor cells, Mps1 kinase has become a potential target for cancer treatment [2] . Over the past years, several dozens of small compounds have been developed to inhibit the Mps1 kinase activity [2] [3] [4] [5] [6] . Recently, NMS-P715 has been described to suppress the growth of medulloblastoma cells, a common malignant brain tumor in children [7] . The anti-proliferative activity of NMS-P715 has been also shown in breast, renal and colon cancer cell lines [8] . A derivative of NMS-P715, Compound 5 (Cpd-5) [9] , has been reported to display higher potency towards Mps1 than NMS-P715 [10] . Although these Mps1 inhibitors have promising results in pre-clinical studies [4, 7, 8] , they also have innate problems as kinase inhibitors [10, 11] . After the initial drug response, tumor cells frequently acquire resistance and become insensitive to treatment [10, 12] . The development of drug resistance in cancer cells is often the consequence of mutations of the targeted kinases [13] . These mutations are typically found in the ATP binding pocket, which renders the binding of inhibitors suboptimal, while retaining kinase activity [14] . A mutation at Cys604 of the Mps1 kinase has been isolated by raising resistance against a number of inhibitors including NMS-P715 [11] as well as Cpd-5, in cell studies [10] . It is positioned in the "hinge loop" region of the kinase domain, which is part of the ATP binding pocket [2] . Gurden et al. described the isolation of the C604W mutant [11] , and a C604Y mutation has been independently described by Koch et al., raising resistance to Cpd-5 [10] . A crystal structure of the Mps1 kinase C604W mutant bound to NMS-P715 [11] showed how this mutation prohibits efficient binding of NMS-P715, suggesting that further development of NMS-P715 derivatives could prove necessary to combat tumor cells conferring drug resistances.
Drug development against kinases can be made more efficient by the availability of automatable direct-readout specific assays, which can be implemented in common laboratory equipment. To detect Mps1 kinase activity in vitro, the myelin basic protein (MBP) is widely employed as a substrate, using radiolabelled ATP or specific phospho-Mps1 antibodies [15] [16] [17] . Alternatively, the KNL1 protein is used as substrate [10] , which is a well-documented Mps1 substrate of kinetochore components [18, 19] . These assays are highly specific for Mps1, but hard to quantify. Another more recently demonstrated way of measuring Mps1 kinase activity is a mobility shift assay described by Naud et al [5] : phosphorylated and non-phosphorylated peptides are separated by electrophoresis based on their charges [13] . This mobility shift assay has been compared with a radiometric assay and found to be more robust [20] .
Here, we first describe a novel and highly specific assay for Mps1 activity by using fluorescence polarization (FP), which is based on the change of tumbling rate of a fluorescentlylabelled KNL1 peptide, monitoring the binding of the 73 kDa Bub1/Bub3 complex as a highthroughput highly specific physiological readout. Using this assay, we determined the IC 50 of NMS-P715 and Cpd-5 for the Mps1 WT and C604Y mutant, and compare it to the K D against these Mps1 variants. We also present the crystal structure of the Mps1 kinase domain bound to Cpd-5, and discuss the structural basis of the inhibition mode of Cpd-5 over NMS-P715 in the Mps1 C604Y/W mutants, and how differences between the binding modes of related inhibitors could be exploited in therapy.
Materials and Methods

Protein production
The plasmid containing a construct of the Mps1 kinase domain (residues 519−808) was a gift from Dr. Nicola Burgess-Brown (Addgene plasmid # 38907) [21] . The Mps1 kinase domain C604Y mutant was produced as previously described [22] .
The pFastBac plasmid containing the GST-tagged full-length Mps1 was a gift from Dr. Geert Kops (Hubrecht Institute, Utrecht, the Netherlands). Recombinant baculovirus was produced according to the Bac-to-Bac protocols (Invitrogen). Spodoptera frugiperda (Sf9) insect cells were infected with the baculovirus and allowed to grow for 72 hours at 27 °C. Cells were harvested by centrifugation and re-suspended in 50 mL of 20 mM KP i , pH 7.5, 150 mM KCl and 1 mM TCEP (buffer A) supplemented with one tablet of Pierce™ Protease Inhibitor Tablets EDTA-free (Thermo Fisher Scientific). Samples were stored at -20°C before proceeding to purification. The re-suspended cells were defrosted at room temperature and lysed by sonication for 1 min at 50% amplitude in a Qsonica Sonicator Q700 (Fisher Scientific). Following centrifugations at 21000 g for 20 minutes at 4 °C, the supernatant was loaded on Glutathione Sepharose 4B (GE Healthcare). After extensive washing in buffer A, the protein was eluted in buffer A supplemented with 10 mM GSH. The sample was then loaded on a Superdex G75 16/60 HiLoad (GE Healthcare) pre-equilibrated in 20 mM HEPES/NaOH, 50 mM KCl, and 3 mM DTT. The protein fractions were pooled together and concentrated to ~10 µM. The concentration of the GST-Mps1 full length was determined by absorption spectrophotometry at 280 nm, with calculated ε = 122.8 mM -1 cm -1 . The purified protein was aliquoted and stored at -80°C.
Bub1 (residues 1−280) and Bub3 were produced as previously described [18] , with modifications. The baculovirus with the Bub1 and Bub3 construct was a gift from Dr. Geert Kops. Sf9 insect cells were infected and allowed to grow for 72 hours at 27 °C. The cell cultures were harvested by centrifugation and re-suspended in 50 mM Tris/HCl, pH 7.7, 1 mM TCEP and 0.05% Tween20 (buffer B) supplemented with 300 mM KCl, 10 mM imidazole and one tablet of Pierce™ Protease Inhibitor Tablets EDTA-free (Thermo Fisher Scientific). Samples were stored at -20°C before proceeding to the purification. The re-suspended cells were defrosted at room temperature and lysed by sonication for 1 min at 50% amplitude in a Qsonica Sonicator Q700 (Fisher Scientific). Following centrifugation at 21000 g for 20 minutes at 4 °C, the supernatant was loaded on a HisTrap HP column (GE Healthcare). After extensive washing in buffer B supplemented with 300 mM KCl and 10 mM imidazole, the protein was eluted with buffer B supplemented with 150 mM imidazole. The sample was then loaded on a Superdex G75 16/60 HiLoad (GE Healthcare) pre-equilibrated in a buffer B supplemented with 100 mM KCl. The protein fractions were pooled together and concentrated. The concentration of the Bub1/Bub3 complex was determined by absorption spectrophotometry at 280 nm, with calculated ε = 101.9 mM -1 cm -1 . The purified protein was aliquoted and stored at -80°C.
Chemicals
Cpd-5 was synthesized as previously described [9] . NMS-P715 was purchased from Merck The excitation and emission wavelengths were 540 nm and 590 nm, respectively and fluorescence polarization (FP) was calculated. All measurements were carried out in duplicate.
To calculate the IC 50 values, the inhibitors were titrated to a reaction mixture containing 20 nM (GraphPad Software, Inc, USA).
where FP max is maximum binding in FP; [c] is inhibitor concentration; FP bg is the background FP value.
Microscale Thermophoresis
The thermophoresis measurements and data analysis were performed as previously described [22] with a slight modification. The DY-547P1 labelled samples were used at a final concentration of 20 nM in Tris buffer (50 mM Tris/HCl, pH 7.4, 150 mM KCl, 1% DMSO, 0.05% Tween20). The measurement was performed at 20% LED and 40% MST power.
Crystallization
The purified Mps1 kinase domain C604Y was co-crystallized with Cpd-5, using the sitting drop Data collection and structure refinement X-ray data were collected on beamline ID30A-3 at the European Synchrotron Radiation Facility (ESRF). The images were integrated with XDS [24] and merged and scaled with AIMLESS [25] . The starting phases were obtained by molecular replacement using PHASER [26] with an available Mps1 structure (PDB code 3HMN) [27] as the search model. Geometric restraints for the compounds were made in AceDRG [28] . The models were built using COOT [29] and refined with REFMAC [30] in iterative cycles; at the beginning and at some stages of the procedure model re-building and refinement parameters adjustment was performed in PDB-REDO [31, 32] . The quality of the models was evaluated by MOLPROBITY [33] . Data collection and refinement statistics are presented in Table 1 .
Results
Cpd--5 and NMS--P715 inhibit Mps1--mediated phosphorylation of KNL1 peptides
To enable quick spectroscopic quantitation of Mps1 activity, we synthesized a fluorescent KNL1 peptide, TMR-KNL1. As shown in Figure 1A Having established the conditions for the FP assay, we measured the ability of Cpd-5 and NMS-P715 to inhibit the activity of Mps1 kinase domain on the KNL1 substrate, by titrating them into our assay mixture ( Figure 2A and Table 2 ). From the titration curves, the IC 50 values were estimated to be 9.2±1.6 nM for Cpd-5 and 139±16 nM for NMS-P715. Cpd-5 and NMS-P715 inhibit the C604Y variant with a significantly lower IC 50 of 170±30 nM for Cpd-5 and 3016±534 nM for NMS-P715, respectively. To validate the result of our new assay, the potency of the inhibitors was assessed also by probing phospo-KNL1 protein with a phospho-specific antibody, which results in similar IC 50 values ( Figure 2C and Table 2 ). These results are fully in agreement to previous studies which showed that expression of the C604Y mutant renders cells more resistant to NMS-P715 than to Cpd-5 [10] .
Binding affinities of Cpd--5 and NMS--P715 to wt and C604Y Mps1
The IC 50 value shows how effective a compound is on a specific assay, but it is not a measurement of the binding of the inhibitor; the latter information is important to understand from a mechanistic perspective the action of inhibitors and the differential effect they assert to mutant proteins. Thus, to evaluate the influence of the C604Y substitution in the inhibition mode, the binding affinities were determined by microscale thermophoresis (MST; Figure 2B and Table 2 ). The MST results show that Cpd-5 binds approximately 300 fold better to the wildtype Mps1 (1.6±0.2 nM) than to the C604Y mutant (471±50 nM); a similar trend is observed for NMS-P715, which binds approximately 375 fold better to the wild-type Mps1 (4.7 ± 2.5) than to the C604Y mutant (1764±204 nM). Notably however, despite the significant reduction in binding affinity to the C604Y mutant, Cpd-5 binds four fold better than NMS-P715. This observation is consistent with the IC 50 measurements in vitro and with cell-based assays [10] ,
where Cpd-5 shows 5-15 times higher potency than NMS-P715 towards inhibiting the C604Y mutant. This is of potential interest for the discovery of compounds that target resistant variants of the kinase, and is important in light of our crystallographic structure of Cpd-5 bound to the C604Y mutant.
Crystal structure of the Mps1 kinase domain bound to Cpd--5
The Mps1 kinase domain C604Y mutant was co-crystalized with Cpd-5. The crystal structure was determined by molecular replacement, at 2.2 Å resolution. There was clear electron density for Cpd-5 in the ATP-binding pocket ( Figure 3A −C) that is unusually deep in the Mps1 kinase.
The overall structure of the protein adapts to a conformation very similar to the previously reported structures [2] . As in many structures of Mps1, the activation loop encompassing residues 676−685 had poor density and has not been included in the model. Thr686 in the P+1 loop has been shown to be auto-phosphorylated in the recombinant protein [2] ; although we tried to model the phosphoryl group of Thr686, it is not well resolved in the electron density map and therefore it has not been included to the structural model. Interestingly, the electron density of a polyethylene glycol molecule, which sometimes encapsulates the catalytic Lys553 due to the crystallization conditions [2] , is not present in our data. In our Cpd-5 bound structure, similar to the NMS-P715 complex structure, the side chain of Lys553 forms a hydrogen bond to the O atom adjacent to the diethyl phenyl ring of Cpd-5. Cpd-5 is stabilized by two additional hydrogen bond interactions with the amide backbone of the "hinge loop" residue, Gly605.
We then compared the interaction of Cpd-5 to Mps1 C604Y, with that of NMS-P715 bound to Mps1 C604W (PDB: 5AP7) [11] . The structure of Mps1 C604W was first re-evaluated with PDB_REDO to result in a model and an electron density map created with the same methodology as for our current structure. The overall binding mode of Cpd-5 was found to be very similar to that of NMS-P715 ( Figure 3D−F) . The electron density of the Cys604 point mutation is clearly resolved in both structures, indicating that the side chains of the substituted Tyr and Trp are well ordered in place. Despite the similar resolution of the NMS-P715 structure (2.45 Å), the orientation of the methylpiperidine moiety is not as well resolved in the electron density map as the methylpiperazine moiety in the Cpd-5 structure. This can be explained by the crystal contact with Thr509, which is poorly ordered. This difference could also be regarded as an artefact of crystallisation rather than a difference in binding mode. The key difference between the two inhibitors is the functional group of the methoxyphenyl moiety. The trifluoromethoxy group of NMS-P715 is positioned at close proximity to the side chains of Trp604 and Ile531. It is reasonable to assume that the two orders of magnitude reduction of the binding affinity is attributed to the increasing chances of steric hindrance between Trp604/Ile531 and this trifluoromethoxy moiety. The methoxyphenyl moiety of Cpd-5 is also positioned in the vicinity to Tyr604. However, the absence of the three fluorine atoms in the functional group reduces the steric hindrance, which results in shifting the position of Cpd-5 towards Tyr604. It is interesting to note that one of the fluorines in NMS-P715 makes a close contact with the Hε 1 of Trp604 (2.3Å) and an even closer contact to the Hε 21 of Gln541 (2.0Å).
Particularly the latter close contact can be regarded as a good example of rare hydrogen bonds of the C-F•••H-N type [34] . 
Discussion
Over the past years, the Mps1 kinase has become a potential target for cancer therapy and an increasing number of Mps1 inhibitors has been published and patented [2] . However, recent reports expectedly suggest that the mutations in Mps1 confer drug resistances in tumor cells [10, 11] . To combat aggressive tumor cells, further development of Mps1 inhibitors is necessary;
yet this has been hindered by labour-intensive assays. Here, we describe a novel fluorescencebased Mps1 kinase assay, which allows us to measure the potency (IC 50 ) of inhibitors more efficiently than conventional methods. Using this assay, and comparing with conventional methods as well as to the actual affinity (K D ) of the compounds towards wild-type and C604Y
Mps1, we find that binding of NMS-P715 is more affected than Cpd-5. This observation, consistent with cell studies showing that the C604Y substitution confers resistance more moderately to Cpd-5 than to NMS-P715 [10] , indicates that combinations of different Mps1 inhibitors can be used to avoid or combat resistance in the clinic, and molecular understanding of the Mps1 interaction with inhibitors is important.
The molecular basis of the non-resistant phenotype of the C604Y mutant towards reversine [10] is supported by measurement of reversine affinity to wild-type and C604Y Mps1 ( Figure 4A and Table 2 ); the affinity of reversine to both Mps1 variants is the same within error.
Comparison of the structure of the C604Y mutant bound to reversine (PDB: 5LJJ, [22] ) clearly
shows why reversine can be accommodated with the same affinity in both Mps1 variants ( Figure 4B) , as there is no steric hindrance with the Tyr604 side chain.
To understand the molecular details behind the potency of Cpd-5 towards wild-type and C604Y
Mps1, we determined the crystal structure of the C604Y variant bound to Cpd-5. Cpd-5 binds to the ATP binding pocket of the Mps1 kinase in a manner similar to NMS-P715. Yet, comparison of the structures of Cpd-5 and NMS-P715 bound to the C604Y and C604W mutant respectively, indicates that the size of the methoxy functional group of the terminal phenyl moiety plays a key role in the steric hindrance with the bulky side chain of Tyr/Trp604. At the same time we observed that different favourable interactions between the methoxy group substitutions and the protein exist. We suggest that substitutions of the methoxy group could be used to develop perhaps less potent Mps1 inhibitors, that could be used to target the 604 mutation, if the need arises in the clinic. For instance, inhibitors for the Trp604 mutant may benefit from a single or a double fluorine substitution on the methoxy group rather than the triple substitution in NMS-
P715.
Our study contributes in understanding the mechanism of resistance in Mps1 kinase inhibitors, suggests a new efficient and specific assay to aid Mps1 inhibitor discovery, and put forwards novel design principles for the further development of this class of inhibitors. 
